- Diagnosis of definite azole-refractory mucosal candidiasis (oral or oropharyngeal
candidiasis or esophageal candidiasis), i.e., patients who have not responded to a
prior 14-day course of fluconazole at a dose of at least 200 mg daily or other azole
(e.g. voriconazole)
- Grade 1 or higher mucosal disease and microscopic or culture confirmation of yeast
- Pregnant female
- Hypersensitivity to anidulafungin or echinocandin therapy
- Hypersensitivity to Tween 80 (polysorbate 80) or tartaric acid
- Abnormal blood chemistries: Bilirubin >2 times the upper limit of normal; AST
(aspartate aminotransferase) or ALT (alanine aminotransferase) > 4 times the upper
limit of normal
- Less than four weeks since prior participation in an investigational drug or device
study with the exception of antiretroviral agents or licensed agents
- Patients taking other systemic antifungal therapies while on this study